Search results for " Coronary Heart Disease"

showing 10 items of 20 documents

The clinical relevance of low-density-lipoproteins size modulation by statins.

2006

The predominance of small, dense low density lipoproteins (LDL) has been accepted as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Treatment Panel III; in fact, LDL size seems to be an important predictor of cardiovascular events and progression of coronary heart disease. Several studies have also shown that the therapeutical modulation of LDL size is of great benefit in reducing the risk of cardiovascular events. Hypolipidemic treatment is able to alter LDL subclass distribution and statins are currently the most widely used lipid-lowering agents. Statins are potent inhibitors of hydroxy-methyl-glutaryl-coenzyme A reductase, the rate-limiting en…

Simvastatinmedicine.medical_specialtyIndolesStatinmedicine.drug_classAtorvastatinFatty Acids MonounsaturatedInternal medicineAtorvastatinmedicineHumansPyrrolesPharmacology (medical)RosuvastatinParticle SizeRosuvastatin CalciumFluvastatinNational Cholesterol Education ProgramPharmacologySulfonamidesVascular diseasebusiness.industryAnticholesteremic Agentsstatins small dense LDL coronary heart disease atherosclerosis prevention therapyGeneral Medicinemedicine.diseaseFluorobenzenesLipoproteins LDLPyrimidinesEndocrinologyCardiovascular DiseasesHeptanoic AcidsSimvastatinlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessPravastatinmedicine.drugFluvastatin
researchProduct

LDL apheresis in a homozygous familial hypercholesterolemic child aged 4.5.

1997

Preliminary experience with the efficacy and safety of dextran sulfate cellulose low-density lipoprotein (LDL) apheresis for the treatment of a 4.5-year-old girl with homozygous familial hypercholesterolemia and coronary artery disease is reported. The decrease of the most atherogenic apolipoprotein B-containing lipoproteins, low-density lipoprotein (LDL) and lipoprotein(a) (Lp [a]), were in the ranges of 63.1-68.7%, and 52.5-58.6%, respectively. The child tolerated LDL apheresis without any clinically significant complications. Therefore, she was submitted to a long-term program of treatment at intervals of 15 days. The experience suggests the possibility of an early beginning of extracorp…

Homozygous Familial Hypercholesterolemiamedicine.medical_specialtyApolipoprotein BBiomedical EngineeringMedicine (miscellaneous)BioengineeringCoronary Disease4.5 years-old girlFamilial hypercholesterolemiaBiomaterialsHyperlipoproteinemia Type IIchemistry.chemical_compoundInternal medicinemedicineCoronary Heart DiseaseHumansHyperlipoproteinemia Type IIbiologybusiness.industryCholesterolHomozygoteGeneral MedicineLipoprotein(a)Low Density Lipoprotein (LDL) apheresis; 4.5 years-old girl; Homozygous Familial Hypercholesterolemia; Coronary Heart Diseasemedicine.diseaseLipoproteins LDLApheresisEndocrinologyCholesterolLow Density Lipoprotein (LDL) apheresischemistryLDL apheresisChild Preschoolbiology.proteinBlood Component Removallipids (amino acids peptides and proteins)FemalebusinessLipoproteinLipoprotein(a)Artificial organs
researchProduct

Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analys…

2017

People with severe mental illness (SMI) – schizophrenia, bipolar disorder and major depressive disorder – appear at risk for cardiovascular disease (CVD), but a comprehensive meta-analysis is lacking. We conducted a large-scale meta-analysis assessing the prevalence and incidence of CVD; coronary heart disease; stroke, transient ischemic attack or cerebrovascular disease; congestive heart failure; peripheral vascular disease; and CVD-related death in SMI patients (N=3,211,768) versus controls (N=113,383,368) (92 studies). The pooled CVD prevalence in SMI patients (mean age 50 years) was 9.9% (95% CI: 7.4-13.3). Adjusting for a median of seven confounders, patients had significantly higher o…

medicine.medical_specialtyCardiovascular disease; bipolar disorder; cerebrovascular disease; congestive heart failure; coronary heart disease; major depression; premature mortality; schizophrenia; severe mental illness03 medical and health sciences0302 clinical medicinesevere mental illnessMedicineCardiovascular disease severe mental illness schizophrenia bipolar disorder major depression coronary heart disease cerebrovascular disease congestive heart failure premature mortalitycoronary heart diseasePsychiatrybipolar disorderFramingham Risk Scorebusiness.industryVascular diseaseIncidence (epidemiology)Hazard ratioCorrectionOdds ratiomedicine.diseaseCardiovascular disease030227 psychiatrycerebrovascular diseaseschizophreniaPsychiatry and Mental healthcongestive heart failurepremature mortalityHeart failureMajor depressive disorderPshychiatric Mental Healthbusinessmajor depressionBody mass index030217 neurology & neurosurgery
researchProduct

Reduced In Vivo Aortic Uptake of Radiolabeled Oxidation-Specific Antibodies Reflects Changes in Plaque Composition Consistent With Plaque Stabilizati…

2004

Objective— Labeled oxidation-specific antibodies (Ox-AB) detect, quantify, and noninvasively image lipid-rich atherosclerotic lesions. However, it is unknown whether Ox-AB detect plaque stabilization. Methods and Results— The aortic uptake of intravenously injected 125 I-MDA2 (Ox-AB to malondialdehyde [MDA]–low-density lipoprotein [LDL]) was quantitated in: (1) LDL receptor−/− mice with established atherosclerosis continued on Western diet (Progression) or switched to chow (Regression) or chow+vitamins E and C (Regression-VIT) for 6 months; and (2) Watanabe rabbits (3- to 57-months old) with naturally evolved atherosclerotic lesions. In mice, the Progression group had more extensive athero…

AgingPathologyArteriosclerosisCardiorespiratory Medicine and HaematologyCardiovascularIodine RadioisotopesMiceEpitopeschemistry.chemical_compoundAntibody SpecificityMalondialdehydeReceptorsMonoclonal2.1 Biological and endogenous factorsMacrophageAetiologyradionuclideAortaFibrous capAntibodies MonoclonalimagingMalondialdehydeImmunohistochemistryLipoproteins LDLMutant StrainsHeart Diseasemedicine.anatomical_structurelipids (amino acids peptides and proteins)RabbitsCardiology and Cardiovascular MedicineOxidation-ReductionBlood vesselmedicine.medical_specialtyoxidationLipoproteinsClinical SciencesBiologyAntibodiesLDLIn vivomedicine.arterymedicineAnimalsHeart Disease - Coronary Heart DiseaseAortaAtherosclerosisMice Mutant StrainsReceptors LDLRadioimmunodetectionCardiovascular System & HematologychemistryImmunostainingLipoproteinArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct

Diagonal ear lobe crease and atherosclerosis : a review of the medical literature and dental implications

2011

In Spain a significant number of individuals die from atherosclerotic disease of the coronary and carotid arteries without having classic risk factors and prodromal symptoms. The diagonal ear lobe crease (DELC) has been characterized in the medical literature as a surrogate marker which can identify high risk patients having occult atherosclerosis. This topic however has not been examined in either the medical or dental literature emanating from Spain. The majority of clinical, angiography and postmortem reports support the premise that DELC is a valuable extravascular physical sign able to distinguish some patients at risk of succumbing to atherosclerosis of the coronary arteries. A minori…

AgingArteriosclerosisGerodontologypanoramic radiographsCoronary Artery DiseaseCardiovascularCoronary artery diseaseCoronary diseasesatherosclerosis diseaseEar Externalmedicine.diagnostic_testStomatognathic DiseasesEar:CIENCIAS MÉDICAS [UNESCO]Heart Diseasemedicine.anatomical_structureOrellaUNESCO::CIENCIAS MÉDICASRadiologyRadiologia dentalcalcified carotid arterymedicine.medical_specialtyPanoramic radiographVital signsArteriosclerosiMalalties coronàriesPanoramicRadiography PanoramicDiagonal ear lobe creasemedicineotorhinolaryngologic diseasesHumansMedical historyEspanyaDental/Oral and Craniofacial DiseaseGeneral DentistryHeart Disease - Coronary Heart DiseaseSurrogate endpointbusiness.industryPreventionReview-ArticleDental radiologyatheromasAtherosclerosismedicine.diseaseOccultExternalRadiographyCoronary arteriesArterioesclerosiOtorhinolaryngologySpainDentistryAngiographySurgerybusiness
researchProduct

Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patients

2010

BACKGROUND: Reducing low-density lipoprotein cholesterol (LDL-C) is the primary goal of therapy in patients with hypercholesterolemia and coronary heart disease (CHD). METHODS: This double blind placebo-controlled study enrolled patients 18 to 75 years of age with primary hypercholesterolemia and establishedCHDwhowere taking a stable daily dose of simvastatin 20 mg. Patients were randomized to ezetimibe/simvastatin 10/20 mg (eze/simva; n 5 56) or simvastatin 40 mg (simva; n 5 56) for 6 weeks. Percent change from baseline in LDL-C, total cholesterol, high-density lipoprotein cholesterol (HDL-C), and triglycerides were assessed by use of the Student t test. The percent of patients achieving L…

MaleSimvastatinSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismCoronary DiseasePharmacologyGastroenterologylaw.inventionchemistry.chemical_compoundRandomized controlled triallawCholesterol absorption inhibitorEzetimibe; simvastatin; coronary heart diseaseNutrition and DieteticsAnticholesteremic AgentsMiddle AgedLipidCoronary heart diseaseCholesterolDrug Therapy CombinationFemalelipids (amino acids peptides and proteins)Cardiology and Cardiovascular Medicinemedicine.drugAdultmedicine.medical_specialtyAdolescentmedicine.drug_classHypercholesterolemiaPharmacotherapyDouble-Blind MethodEzetimibeInternal medicineInternal MedicinemedicineHumansTriglyceridesCholesterol absorption inhibitorAgedCholesterolbusiness.industryCholesterol HDLCholesterol absorption inhibitor; Coronary heart disease; Ezetimibe; Lipids; SimvastatinCholesterol LDLEzetimibeClinical trialchemistrySimvastatinAzetidinesEzetimibe/simvastatinbusinessJournal of Clinical Lipidology
researchProduct

Atherosclerosis, inflammation and Chlamydia pneumoniae

2009

Coronary heart disease is the single most common cause of illness and death in the developed world. Coronary atherosclerosis is by far the most frequent cause of ischemic heart disease, and plaque disruption with superimposed thrombosis is the main cause of the acute coronary syndromes of unstable angina, myocardial infarction, and sudden death. Atherosclerosis is the result of a complex interaction between blood elements, disturbed flow, and vessel wall abnormality, involving several pathological processes: inflammation, with increased endothelial permeability, endothelial activation, and monocyte recruitment; growth, with smooth muscle cell proliferation, migration, and matrix synthesis; …

medicine.medical_specialtyPathologyATHEROSCLEROSIS INFECTIONUnstable anginabusiness.industryInflammationChlamydia Coronary atherosclerosis Coronary heart disease PhlogosisReviewmedicine.diseaseSudden deathThrombosisEndothelial activationInternal medicinemedicineCardiologyMyocardial infarctionmedicine.symptomCardiology and Cardiovascular MedicinebusinessCoronary atherosclerosisCalcification
researchProduct

Cost-effectiveness of optimized adherence to prevention guidelines in European patients with coronary heart disease : results from the EUROASPIRE IV …

2018

Background: This study aims to assess the cost-effectiveness of optimized guideline adherence in patients with a history of coronary heart disease. Methods: An individual-based decision tree model was developed using the SMART risk score tool which estimates the 10-year risk for recurrent vascular events in patients with manifest cardiovascular disease (CVD). Analyses were based on the EUROASPIRE IV survey. Outcomes were expressed as an incremental cost-effectiveness ratio (ICER). Results: Data from 4663 patients from 13 European countries were included in the analyses. The mean estimated 10-year risk for a recurrent vascular event decreased from 20.13% to 18.61% after optimized guideline a…

MaleCardiac & Cardiovascular SystemsCost effectivenessmedicine.medical_treatmentCost-Benefit AnalysisCoronary DiseaseDisease030204 cardiovascular system & hematology0302 clinical medicineOlder patientsMedicine030212 general & internal medicineguidelinesEUROASPIRE1102 Cardiorespiratory Medicine and Haematologyhealth care economics and organizationsBIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina.Framingham Risk ScoreSecondary preventionASSOCIATIONMiddle AgedhumanitiesCoronary heart diseaseEuropeDENSITY-LIPOPROTEIN CHOLESTEROLPractice Guidelines as TopicTRIALFemaleGuideline AdherenceCardiology and Cardiovascular MedicineLife Sciences & Biomedicinesecondary prevention ; guidelines ; cost-effectiveness ; coronary heart disease ; EUROASPIREsecondary preventionmedicine.drugINTERVENTIONSmedicine.medical_specialtyEZETIMIBEGuidelinesEVENTS03 medical and health sciencesEzetimibeInternal medicineHumansIn patientcoronary heart diseaseBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine.cost-effectivenessMETAANALYSISAgedScience & Technologybusiness.industryDecision TreesSMOKING-CESSATIONCoronary heart diseaseTHRESHOLDSCardiovascular System & HematologyCardiovascular System & CardiologySmoking cessationCost-effectivenessbusinessSTATIN TREATMENT
researchProduct

The clinical significance of small, dense low-density lipoproteins

2006

Peak size of low-density lipoproteins (LDL) in humans does not show a normal, but a bimodal distribution and can be separated into two phenotypes, that differ in size, density, physicochemical composition, metabolic behavior, and atherogenicity. These phenotypes have been assigned as pattern A when larger, more buoyant LDL and pattern B when smaller, more dense LDL predominate. Small dense LDL correlates negatively with plasma HDL levels and positively with plasma triglyceride concentrations and is associated with the metabolic syndrome and increased risk for cardiovascular disease. LDL size seems to be an important predictor of cardiovascular events and progression of coronary heart diseas…

biologybusiness.industryCholesterylester transfer proteinBiophysicsLow densitybiology.proteinMedicineClinical significancebusinessatherosclerosis coronary heart disease prevention small dense LDL
researchProduct

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart diseas…

2013

AIMS: The first aim was to critically evaluate the extent to which familial hypercholesterolaemia (FH) is underdiagnosed and undertreated. The second aim was to provide guidance for screening and treatment of FH, in order to prevent coronary heart disease (CHD).METHODS AND RESULTS: Of the theoretical estimated prevalence of 1/500 for heterozygous FH, <1% are diagnosed in most countries. Recently, direct screening in a Northern European general population diagnosed approximately 1/200 with heterozygous FH. All reported studies document failure to achieve recommended LDL cholesterol targets in a large proportion of individuals with FH, and up to 13-fold increased risk of CHD. Based on prev…

medicine.medical_specialtyStatinAtherosclerosis; Cardiovascular disease; Cholesterol; Coronary heart disease; Low-density lipoproteinSettore MED/09 - Medicina Internamedicine.drug_classPopulationCHILDRENFamilial hypercholesterolemiaBile acid bindingCOST-EFFECTIVENESS ANALYSIS030204 cardiovascular system & hematologyLDL-CHOLESTEROLDIAGNOSIS03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEzetimibeInternal medicineDiabetes mellitusmedicineMANAGEMENT030212 general & internal medicineeducationHealth aging / healthy living Cardiovascular diseases [IGMD 5]Alirocumabeducation.field_of_studyCYTOKINE PATTERN CHANGEbusiness.industryLow-density lipoproteinmedicine.diseaseAtherosclerosisCardiovascular diseaseLomitapideDENSITY-LIPOPROTEIN APHERESIS3. Good healthASSOCIATION EXPERT PANELCoronary heart diseaseEndocrinologyCholesterolchemistryCARDIOVASCULAR-DISEASEAtherosclerosiCardiology and Cardiovascular MedicinebusinessSTATIN TREATMENTmedicine.drugEuropean Heart Journal
researchProduct